What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1).

What question did this study set out to answer?

To evaluate the safety and efficacy of RM-001 in achieving transfusion independence in patients with transfusion-dependent β-thalassemia.

December 8, 2025BloodOpen Access

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

View Full Paper

Ask AI

Bookmark

Authors

RLRongrong LiuCentral South University LWLi WangQingdao University SLSixi LiuNational University of Ireland, Maynooth

Discussion

Member takes

Implication

Phase 1 trial demonstrates RM-001 improves fetal hemoglobin and ensures transfusion independence in patients with β-thalassemia, suggesting a curative potential.

Key Points

To evaluate the safety and efficacy of RM-001 in achieving transfusion independence in patients with transfusion-dependent β-thalassemia.
Two clinical trials conducted: an investigator-initiated trial and a Phase 1 trial
Participants aged 6 to 35 years with significant previous transfusion history
Assessment of transfusion independence after treatment with RM-001 for 24 months
All 19 patients achieved transfusion independence after RM-001 treatment
No serious adverse events were reported and all adverse events resolved
Stabilized total hemoglobin and fetal hemoglobin levels observed over 18 months

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d610 https://doi.org/10.1182/blood-2025-4308

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

View Full Paper

Ask AI

Bookmark

Authors

RLRongrong LiuCentral South University LWLi WangQingdao University SLSixi LiuNational University of Ireland, Maynooth

Discussion

Member takes

Implication

Phase 1 trial demonstrates RM-001 improves fetal hemoglobin and ensures transfusion independence in patients with β-thalassemia, suggesting a curative potential.

Key Points

To evaluate the safety and efficacy of RM-001 in achieving transfusion independence in patients with transfusion-dependent β-thalassemia.
Two clinical trials conducted: an investigator-initiated trial and a Phase 1 trial
Participants aged 6 to 35 years with significant previous transfusion history
Assessment of transfusion independence after treatment with RM-001 for 24 months
All 19 patients achieved transfusion independence after RM-001 treatment
No serious adverse events were reported and all adverse events resolved
Stabilized total hemoglobin and fetal hemoglobin levels observed over 18 months

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d610 https://doi.org/10.1182/blood-2025-4308

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark